Pathological Changes After Autologous Formalin-Fixed Tumor Vaccine Therapy Combined With Temozolomide for Glioblastoma —Three Case Reports—

Noriaki SAKAMOTO; Eiichi ISHIKAWA; Tetsuya YAMAMOTO; Kaishi SATOMI; Kei NAKAI; Masayuki SATO; Takao ENOMOTO; Yukio MORISHITA; Shingo TAKANO; Tadao OHNO; Koji TSUBOI; Akira MATSUMURA

doi:10.2176/nmc.51.319

Case Reports

Pathological Changes After Autologous Formalin-Fixed Tumor Vaccine Therapy Combined With Temozolomide for Glioblastoma

—Three Case Reports—

Noriaki SAKAMOTO, Eiichi ISHIKAWA, Tetsuya YAMAMOTO, Kaishi SATOMI, Kei NAKAI, Masayuki SATO, Takao ENOMOTO, Yukio MORISHITA, Shingo TAKANO, Tadao OHNO, Koji TSUBOI, Akira MATSUMURA

Author information

Noriaki SAKAMOTO
Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Eiichi ISHIKAWA
Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Tetsuya YAMAMOTO
Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Kaishi SATOMI
Department of Pathology, Institute of Basic Medical Sciences, University of Tsukuba
Kei NAKAI
Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Masayuki SATO
Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Takao ENOMOTO
Department of Neurosurgery, Tsukuba Central Hospital
Yukio MORISHITA
Department of Pathology, Institute of Basic Medical Sciences, University of Tsukuba
Shingo TAKANO
Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Tadao OHNO
Advanced Research Institute for Science and Engineering, Waseda University
Koji TSUBOI
Proton Medical Research Center, Graduate School of Comprehensive Human Sciences, University of Tsukuba
Akira MATSUMURA
Department of Neurosurgery, Graduate School of Comprehensive Human Sciences, University of Tsukuba

Keywords: vaccine therapy, tumor-specific immunotherapy, chemotherapy, malignant glioma, temozolomide

JOURNAL OPEN ACCESS

2011 Volume 51 Issue 4 Pages 319-325

DOI https://doi.org/10.2176/nmc.51.319

Details

Abstract

Temozolomide (TMZ), an alkylating agent widely used for patients with glioblastoma multiforme (GBM), has the potential to enhance the acquired immune response to GBM. Here, we describe 3 cases of GBM patients treated with autologous formalin-fixed tumor vaccine (AFTV) combined with TMZ. All cases demonstrated pathological changes associated with the therapy. After a 4-week break from the standard initial treatments, 1 patient with primary GBM and 2 patients with secondary GBM received adjuvant TMZ for 5 days combined with AFTV injection and were subsequently treated with multiple cycles of adjuvant TMZ for 5 days every 28 days (AFTV/TMZ therapy). Adverse effects related to AFTV plus TMZ were very minor in all patients. Magnetic resonance imaging revealed partial response in 2 patients. CD3⁺CD8⁺ lymphocytes were frequently detected in surgical specimens and MIB-1 labeling index in 2 cases decreased after AFTV/TMZ therapy. AFTV/TMZ therapy is suitable for larger scale clinical trials.

Corresponding author

Register with J-STAGE for free!